Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- 1 January 2014
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 146 (1), 96-109.e1
- https://doi.org/10.1053/j.gastro.2013.06.010
Abstract
No abstract availableKeywords
Funding Information
- Janssen Research and Development
This publication has 20 references indexed in Scilit:
- Ulcerative colitisThe Lancet, 2012
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Does Anti-TNF Therapy Reduce the Requirement for Surgery in Ulcerative Colitis? A Systematic ReviewCurrent Drug Targets, 2011
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor αmAbs, 2010
- Colectomy rate in acute severe ulcerative colitis in the infliximab eraDigestive and Liver Disease, 2008
- Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double‐blind, placebo‐controlled, dose‐ranging studyArthritis & Rheumatism, 2008
- Low Colectomy Rates in Ulcerative Colitis in an Unselected European Cohort Followed for 10 YearsGastroenterology, 2007
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Course of ulcerative colitis: Analysis of changes in disease activity over yearsGastroenterology, 1994